A resolution expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill creates that it is the sense of the Senate that— FDA policies affecting access to medication abortion care in the United States must be based on transparent scientific review of the full body of gold-standard medical. It relies on grants, reporting requirements, compliance mandates, and product standards. The main policy areas are Agriculture, Finance, Housing, and Healthcare.
Who Benefits and How
Patients and health care consumers affected by the bill could gain revenue opportunities, Homeowners, tenants, or housing market participants affected by the bill could gain revenue opportunities, and Financial services firms and customers affected by the bill could gain revenue opportunities.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties.
Key Provisions
- Creates that it is the sense of the Senate that— FDA policies affecting access to medication abortion care in the United States must be based on transparent scientific review of the full body of gold-standard medical...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill creates that it is the sense of the Senate that— FDA policies affecting access to medication abortion care in the United States must be based on transparent scientific review of the full body of gold-standard medical.
Key Policy Areas
Agriculture, Finance, Housing, Healthcare
Primary Purpose
The bill creates that it is the sense of the Senate that— FDA policies affecting access to medication abortion care in the United States must be based on transparent scientific review of the full body of gold-standard medical.
Policy Domains
Whole bill
Identified Gains
- Patients and health care consumers affected by the bill
- Homeowners, tenants, or housing market participants affected by the bill
- Financial services firms and customers affected by the bill
- Agricultural producers and rural communities affected by the bill
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
Sponsors
Legislative Progress
In CommitteeReferred to the Committee on Health, Education, Labor, and Pensions. …
Submitted in Senate
Ms. Warren (for herself, Ms. Baldwin, Mr. Schumer, Mr. Wyden, …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology